{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:01:11Z","timestamp":1774558871381,"version":"3.50.1"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The optimal adjuvant treatment approach for muscle-invasive bladder cancer (MIBC) remains unsettled. The IMvigor011 trial demonstrated that circulating tumor DNA (ctDNA)\u2013guided adjuvant atezolizumab improves outcomes and advances precision oncology in this setting. However, the socioeconomic value of this biomarker-driven strategy is unclear. We therefore assessed the economic value of ctDNA-guided therapy in this postoperative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>We constructed a three-state Markov model to estimate costs, quality-adjusted life-years (QALYs), incremental net monetary benefit (INMB), and incremental cost-effectiveness ratios (ICERs) in patients with MIBC. The model compared a ctDNA-guided adjuvant atezolizumab strategy with the standard of care (SOC) from a US health care payer perspective. Cost-effectiveness was assessed across willingness-to-pay (WTP) thresholds of $50,000-$150,000 in US dollars (USD) per QALY, and model robustness was examined through comprehensive sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Over a 5-year horizon, the ctDNA-guided strategy yielded 3.05 QALYs at a cost of $78,796 USD, compared with 2.92 QALYs and $131,601 USD for SOC. This corresponded to an ICER of \u2013$397,163 USD per QALY gained, demonstrating dominance through greater benefit at lower cost. Sensitivity analyses confirmed that the ctDNA-guided approach was consistently cost-effective across all WTP thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ctDNA-guided atezolizumab adjuvant therapy proves to be a cost-effective strategy for MIBC, optimizing health care resource allocation and reducing overtreatment while improving patient outcomes. More standardized ctDNA testing protocols and transparent reporting of ctDNA status distributions are essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-01242","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:59:09Z","timestamp":1774555149000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Circulating Tumor DNA\u2013Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6750-0934","authenticated-orcid":true,"given":"Zihan","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-3653","authenticated-orcid":false,"given":"Yunkai","family":"Qie","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8554-9685","authenticated-orcid":false,"given":"Shan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8790-9985","authenticated-orcid":false,"given":"Rongjiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1580-1577","authenticated-orcid":false,"given":"Chong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2009-4468","authenticated-orcid":false,"given":"Zhouliang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8191-7550","authenticated-orcid":true,"given":"Houyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0430-1302","authenticated-orcid":false,"given":"Yuda","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2575-0516","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8675-5524","authenticated-orcid":true,"given":"Hailong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09912.x"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00004-8"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.139"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401726"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1272-6"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01023-9"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_6_12_2","volume-title":"Medicare Part B Drug Average Sales Price (ASP) Pricing Files","author":"Centers for Medicare & Medicaid Services","year":"2025","unstructured":"Centers for Medicare & Medicaid Services: Medicare Part B Drug Average Sales Price (ASP) Pricing Files. 2025"},{"key":"e_1_3_6_13_2","volume-title":"Clinical Laboratory Fee Schedule (CLFS) Files","author":"Services CfMM: Centers for Medicare & Medicaid Services","year":"2025","unstructured":"Services CfMM: Centers for Medicare & Medicaid Services: Clinical Laboratory Fee Schedule (CLFS) Files. 2025"},{"key":"e_1_3_6_14_2","volume-title":"Inpatient Prospective Payment System","author":"Services CfMM","year":"2025","unstructured":"Services CfMM: Inpatient Prospective Payment System. 2025"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.124"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4503"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2045"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2414159"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06225-y"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113112"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04030-w"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-01242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:59:10Z","timestamp":1774555150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-01242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":22,"alternative-id":["10.1200\/OP-25-01242"],"URL":"https:\/\/doi.org\/10.1200\/op-25-01242","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-01242"}}